Biotechnology and Big Pharma’s Imperative for M&A

Biotechnology and Big Pharma’s Imperative for M&A explores the forces reshaping healthcare as large pharmaceutical companies face significant revenue loss from upcoming patent expirations.

Drawing on industry data and Emerald’s research, the paper highlights why Small and Mid Cap biotech companies have become critical to innovation—and how a new wave of M&A activity is creating opportunity beneath the surface.

Read the full paper Here: WHITEPAPER

This material is furnished for informational use only and does not constitute the provision of investment, legal or tax advice.  It is not prepared with respect to the specific investment objectives, financial situation or particular needs of any specific person.  The information contained in this article was obtained from sources deemed reliable.  The information and calculations are not guaranteed as to their accuracy, timeliness or completeness by Emerald.  Any opinions contained in this article represent the judgment of the authors as of the publication date.  The information contained in this article and the opinions expressed herein are subject to change without notice.  Past performance is no guarantee of future results.  Neither the information in this article nor any opinion expressed herein constitutes an offer nor recommendation to buy or sell any security or financial instrument.  Accounts managed by Emerald’s affiliated advisory firms may take positions from time to time in securities discussed in this article.